Varicella Vaccination With Pulmicort

Phase 4CompletedNCT00641446

AstraZeneca250 enrolled

Overview

A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

250

Conditions

Asthma

Interventions

budesonideDRUG

varicella zoster virusDRUG

Eligibility

Sex: ALLMin age: 10 MonthsMax age: 8 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children between the age of 10 months and 8 years, * have asthma or shown recent signs suggesting asthma, * have a parent or guardian willing to comply with study requirements Exclusion Criteria: * Varicella zoster immune globulin (VZIG) within 5 months prior to immunization, * Previous varicella immunization, * an immunization or allergy immunotherapy 4 weeks prior to immunization, * Severe asthma, * have another persistent lung disease, * have a planned hospitalization for the duration of study

Outcomes

Primary Outcomes

Seroconversion level

Time frame: Week 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.